China’s Mindrank AI raised $52 million in a Series B to advance MDR-001, its AI-discovered oral small-molecule GLP-1 receptor agonist. The program is in Phase III trials for obesity in China, with the company citing the need to scale its AI-native discovery and clinical execution. The financing supports both late-stage development of MDR-001 and expansion of its preclinical pipeline. In parallel, the broader oral GLP-1 category continues attracting attention as pharma and biotech compete to shift obesity treatment from injections toward pills. For investors and peers, the Mindrank raise underscores how quickly computational platforms are being tied to late-stage asset delivery in metabolic franchises, even outside the traditional leading GLP-1 incumbents.